204 related articles for article (PubMed ID: 21042306)
1. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.
Kontoyiannis DP
Bone Marrow Transplant; 2011 Feb; 46(2):165-73. PubMed ID: 21042306
[TBL] [Abstract][Full Text] [Related]
2. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
3. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
4. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic SCT in patients with a history of invasive fungal infection.
Zhang P; Song A; Wang Z; Feng S; Qiu L; Han M
Bone Marrow Transplant; 2009 Apr; 43(7):533-7. PubMed ID: 19104496
[TBL] [Abstract][Full Text] [Related]
6. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
[TBL] [Abstract][Full Text] [Related]
7. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies.
Leather HL; Wingard JR
Blood Rev; 2006 Sep; 20(5):267-87. PubMed ID: 16781028
[TBL] [Abstract][Full Text] [Related]
8. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation.
Michallet M; Ito JI
J Clin Oncol; 2009 Jul; 27(20):3398-409. PubMed ID: 19487382
[TBL] [Abstract][Full Text] [Related]
9. Antifungal therapy strategies in hematopoietic stem-cell transplant recipients: early treatment options for improving outcomes.
Chandrasekar P; Ljungman PT
Transplantation; 2008 Jul; 86(2):183-91. PubMed ID: 18645475
[TBL] [Abstract][Full Text] [Related]
10. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
13. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
Maertens J
Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic antifungal agents used after lung transplantation.
Marino E; Gallagher JC
Ann Pharmacother; 2010 Mar; 44(3):546-56. PubMed ID: 20179260
[TBL] [Abstract][Full Text] [Related]
16. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for invasive fungal infections in haematopoietic stem cell transplantation.
Camps IR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S119-23. PubMed ID: 19013335
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W; Wang Cheng J; Tong KB; Seifeldin R
Clin Ther; 2008 May; 30(5):964-73. PubMed ID: 18555943
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.
Cornely OA; Aversa F; Cook P; Jones B; Michallet M; Shea T; Vallejo C
Eur J Haematol; 2011 Oct; 87(4):289-301. PubMed ID: 21752098
[TBL] [Abstract][Full Text] [Related]
20. Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients.
Hamza NS; Ghannoum MA; Lazarus HM
Bone Marrow Transplant; 2004 Sep; 34(5):377-89. PubMed ID: 15247928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
